24 citations
,
January 2003 in “Journal of Investigative Dermatology” Blocking a specific receptor slows down hair loss in mice.
58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
3 citations
,
March 2014 in “Journal of Industrial Microbiology & Biotechnology” Scientists found a new gene in a bacterium that can modify an immunosuppressant drug, potentially helping to treat hair loss.
January 2003 in “Journal of Clinical Dermatology” Cyclosporin promotes hair growth by boosting cell growth and reducing cell death.
30 citations
,
December 2009 in “The FASEB Journal” Fluphenazine and iloprost can induce hair growth.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
36 citations
,
June 2021 in “Experimental & Molecular Medicine” Targeting Hedgehog signaling may help treat ligamentum flavum fibrosis.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
A protein called sFRP4 can partly inhibit hair growth.
19 citations
,
September 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.
1 citations
,
July 2026 in “Dermatology and Therapy” JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
April 2021 in “Journal of Investigative Dermatology” Blocking DPP4 can help prevent fat loss and skin fibrosis.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
January 2025 in “Journal of Bioresource Management” ATR is crucial for DNA repair and cell survival after UV exposure.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
April 2012 in “Journal of evolution of medical and dental sciences” No effective treatment exists to stimulate hair growth in atrichia with papular lesions.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
1 citations
,
January 2020 in “Seoul National University Open Repository (Seoul National University)” PDE3 inhibitor may help treat hair loss by promoting hair growth.
May 2023 in “Blood cancer discovery” Finasteride reduces AML cell growth by inhibiting androgen receptors.
October 2017 in “Institutional Repositories DataBase (IRDB)” Polyacetylene compounds from Panax ginseng may slow hair growth.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
13 citations
,
July 2024 in “Heart Failure Reviews” The apelinergic system might protect the heart from damage caused by doxorubicin.
6 citations
,
October 1998 in “Experimental Dermatology” Normal skin results from interactions between EGF and the Tabby mutation.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.